About Albumedix
Albumedix is a company based in Lyngby (Denmark) founded in 2016 was acquired by Sartorius in August 2022. The company has 106 employees as of December 31, 2021.
- Headquarter Lyngby, Denmark
- Employees 106 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Albumedix Ltd
-
Annual Revenue
$38.24 M (USD)21as on Dec 31, 2021
-
Net Profit
$6.61 M (USD)-2as on Dec 31, 2021
-
EBITDA
$7.78 M (USD)-2as on Dec 31, 2021
-
Latest Funding Round
$335.35 K (USD), Grant
Sep 01, 2020
-
Investors
Sartorius
& 1 more
-
Employee Count
106
as on Dec 31, 2021
-
Acquired by
Sartorius
(Aug 09, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Albumedix
Investors in Albumedix
Albumedix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Sartorius and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Laboratory and biopharmaceutical equipment is developed for production processes.
|
Locked | Locked | Locked |
Investor details for Albumedix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Albumedix
Investment portfolio details for Albumedix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Albumedix
Detailed financials for Albumedix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Albumedix Comparisons
Peer comparison for Albumedix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Albumedix
Detailed competitors of Albumedix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Albumedix
Complete news archive for Albumedix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Albumedix
Albumedix was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Albumedix is headquartered in Lyngby, Denmark. It is registered at Lyngby, Region Hovedstaden, Denmark.
As of Dec 31, 2021, the latest employee count at Albumedix is 106.
Annual revenue of Albumedix is $38.24M as on Dec 31, 2021.
Albumedix was spun-out as a fully owned subsidiary from the Biopharma activities of Novozymes. Albumedix helps biopharmaceutical companies improve patient outcomes with a range of albumin-based products and technologies that facilitate the development of biotherapeutics. Named Recombumin, Albumedixs recombinant albumins are used in the pharmaceutical industry to stabilize drugs and vaccines, extend drug half-life and improve drug delivery (Albumedix offers a first and second generation version of this drug delivery technology under the name Veltis). Their products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies. They also use this expertise to strengthen our own drug pipeline. since 2006, Merck has used Albumedixs solutions to produce two vaccines used to treat millions of children worldwide against measles, mumps, rubella and chicken pox. In 2014, Veltis got its commercial breakthrough when GlaxoSmithKline launched a diabetes drug that utilizes the technology, allowing patients to dose weekly instead of daily. In Jan 2016, Albumedix acquired Eleven Therapeutics proprietary Supermin albumin variant assets.
Albumedix has 2 investors. Key investors include Sartorius, and European Union.